Project Grant R01HL180754
Award Date 9/15/25
Completion Date 6/30/29
Dollars Obligated $536K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate new strategies for preventing immune rejection of hematopoietic stem cell grafts in transplantation. The $725,971 award, with a performance period from August 15, 2025 to May 31, 2030, will fund research at the University of California, San Diego (UCSD) to explore the use of gene editing to silence mismatched human leukocyte...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,781 to Mogling Bio Inc. to develop a therapeutic regimen that can attenuate aging of human hematopoietic stem cells (HSCs). The central goal is to validate the use of the drug CASIN to restore CDC42-regulated polarity and rejuvenate aged human HSCs ex vivo. This research aims to benefit bone marrow HSC transplant patients...
- This Project Grant award of $125,532.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the disruption of the clonal architecture of human hematopoietic stem cells driven by high-effect somatic and germline genetic variants, and identify the resulting phenotypic changes that lead to impaired stem cell function and increased disease risk with aging. The research will utilize a mitochondrial lineage tracing...
- This $147,486 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Southern California to investigate the heterogeneous intercellular signaling of hematopoietic stem and progenitor cells (HSPCs) and its changes around the circadian clock. The research aims to advance understanding of how HSPC cell-cell communication and gene expression patterns within the bone marrow microenvironment are...
- This Project Grant award of $735,085 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Case Western Reserve University to investigate modulating the Heat Shock Transcription Factor 1 (HSF1) as a means to transform detrimental age-related clonal hematopoiesis (CH) into a state favoring normal blood cell production while preventing CH progression. The research aims to understand how deleting HSF1 along with the CH-associated...
- This $292,500 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to identify novel microproteins associated with normal hematopoiesis and hematopoietic diseases. The project will leverage existing transcriptomic and translation data to produce a comprehensive catalog of microproteins expressed in different hematopoietic cell types. This inter-disciplinary research conducted by the Sanford Burnham Prebys Medical Discovery...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This $153,117 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the recipient's independent research career as an academic hematopathology physician-scientist. The key objectives are to study hematopoietic stem and progenitor cell (HSPC) crosstalk and transplantation, with the overarching goal of improving HSPC transplantation outcomes. The award period runs from August 1, 2025 to July 31,...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $162,486 to The Leland Stanford Junior University to engineer hematopoietic stem cells to produce B cells that secrete antibodies against PCSK9, a promising treatment for hypercholesterolemia. The research aims to develop a durable, lifelong therapeutic solution by using CRISPR/Cas9 genome editing to target an engineered antibody transgene into a safe-harbor site in...
- This Project Grant award of $153,696.00 from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), supports research to elucidate the developmental origin and functional characteristics of a myeloid-biased hematopoietic stem cell (MY-HSC) population identified in the fetal liver. The research aims to investigate the localization and frequency of these MY-HSCs during prenatal development using advanced techniques like flow cytometry,...